These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28604461)

  • 1. Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
    van Haaften C; van Eendenburg J; Boot A; Corver WE; Haans L; van Wezel T; Trimbos JB
    Int J Gynecol Cancer; 2017 Oct; 27(8):1571-1578. PubMed ID: 28604461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 3. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    Dougherty BA; Lai Z; Hodgson DR; Orr MCM; Hawryluk M; Sun J; Yelensky R; Spencer SK; Robertson JD; Ho TW; Fielding A; Ledermann JA; Barrett JC
    Oncotarget; 2017 Jul; 8(27):43653-43661. PubMed ID: 28525389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
    BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
    Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
    Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    Friedlander M; Matulonis U; Gourley C; du Bois A; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Shirinkin V; Selle F; Fielding A; Lowe ES; McMurtry EL; Spencer S; Rowe P; Mann H; Parry D; Ledermann J
    Br J Cancer; 2018 Oct; 119(9):1075-1085. PubMed ID: 30353045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    Cecere SC; Giannone G; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Carella C; Scollo P; Ghizzoni V; Raspagliesi F; Di Napoli M; Mazzoni E; Marchetti C; Bergamini A; Orditura M; Valabrega G; Scambia G; Maltese G; De Matteis E; Cardalesi C; Loizzi V; Boccia S; Naglieri E; Scandurra G; Pignata S
    Gynecol Oncol; 2020 Jan; 156(1):38-44. PubMed ID: 31699415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
    Stewart J; George A; Banerjee S
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
    Eetezadi S; Evans JC; Shen YT; De Souza R; Piquette-Miller M; Allen C
    Mol Pharm; 2018 Feb; 15(2):472-485. PubMed ID: 29283581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    Marchetti C; Rosati A; Scaletta G; Pietragalla A; Arcieri M; Ergasti R; Palluzzi E; Scambia G; Fagotti A
    Gynecol Oncol; 2019 Dec; 155(3):400-405. PubMed ID: 31606285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
    van Haaften C; Boot A; Corver WE; van Eendenburg JD; Trimbos BJ; van Wezel T
    J Exp Clin Cancer Res; 2015 Apr; 34(1):38. PubMed ID: 25907439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    Tomao F; Musacchio L; Di Mauro F; Boccia SM; Di Donato V; Giancotti A; Perniola G; Palaia I; Muzii L; Benedetti Panici P
    Gynecol Oncol; 2019 Jul; 154(1):138-143. PubMed ID: 31079832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
    Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
    Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.